MedTrace Logo

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects

NCT01695876 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2015-03-04

No results posted yet for this study

Summary

Study to evaluate the safety, tolerability, PK, PD, and food effect of AMG 357 in healthy subjects

Conditions

  • Inflammatory Disease

Interventions

DRUG

AMG 357

Oral administration available in varying dose strength.

DRUG

Placebo

Matching placebo to AMG 357 containing no active drug

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-09-30
Completion
2014-10-31

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01695876 on ClinicalTrials.gov